Cargando…

Breakthrough infections with SARS-CoV-2 omicron efficiently boost antibodies from previous BNT162b2 vaccinations

OBJECTIVE: To investigate whether SARS-CoV-2 omicron breakthrough infection in individuals after three doses of wildtype-based BNT162b2 increases antibody levels measured by a commercially available wildtype-based immunoassay. METHODS: 16 of 21 individuals in a BNT162b2 vaccination cohort (recruited...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perkmann, Thomas, Springer, David N., Mucher, Patrick, Wolzt, Michael, Weseslindtner, Lukas, Haslacher, Helmuth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier Ltd. 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10299948/ https://www.ncbi.nlm.nih.gov/pubmed/37398629 http://dx.doi.org/10.1016/j.jcvp.2023.100157

Ejemplares similares

Serum antibody response to BNT162b2 after natural SARS‐CoV‐2 infection
por: Perkmann, Thomas, et al.
Publicado: (2021)

Comparison of five Anti-SARS-CoV-2 antibody assays across three doses of BNT162b2 reveals insufficient standardization of SARS-CoV-2 serology
por: Perkmann, Thomas, et al.
Publicado: (2023)

Initial SARS-CoV-2 vaccination response can predict booster response for BNT162b2 but not for AZD1222
por: Perkmann, Thomas, et al.
Publicado: (2021)

Anti-Spike Protein Assays to Determine SARS-CoV-2 Antibody Levels: a Head-to-Head Comparison of Five Quantitative Assays
por: Perkmann, Thomas, et al.
Publicado: (2021)

Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
por: Springer, David Niklas, et al.
Publicado: (2022)

Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Breakthrough Infections in BNT162b2-Vaccinated Health Care Workers
por: Lange, Bettina, et al.
Publicado: (2021)

Immune Responses After Vaccination With Primary 2-Dose ChAdOx1 Plus a Booster of BNT162b2 or Vaccination With Primary 2-Dose BNT162b2 Plus a Booster of BNT162b2 and the Occurrence of Omicron Breakthrough Infection
por: Choi, Seong-Ho, et al.
Publicado: (2023)

Boosting BNT162b2 vaccine efficacy in CLL
por: Bhat, Seema A., et al.
Publicado: (2022)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern
por: Graham, Carl, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

BNT162b2 Protection against the Omicron Variant in Children and Adolescents
por: Price, Ashley M., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Omicron breakthrough infections in vaccinated or previously infected hamsters
por: Zhou, Jie, et al.
Publicado: (2023)

Spike Protein Antibodies Mediate the Apparent Correlation between SARS-CoV-2 Nucleocapsid Antibodies and Neutralization Test Results
por: Perkmann, Thomas, et al.
Publicado: (2021)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
por: Collie, Shirley, et al.
Publicado: (2021)

Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)

Reduced Neutralization Efficacy against Omicron Variant after Third Boost of BNT162b2 Vaccine among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2023)

Ad26.COV2.S boosts antibody and T-cell responses following BNT162b2 vaccination
por: Iketani, Sho, et al.
Publicado: (2021)

The second dose of the BNT162b2 mRNA vaccine does not boost SARS-CoV-2 neutralizing antibody response in previously infected subjects
por: Vicenti, Ilaria, et al.
Publicado: (2021)

Limited Neutralization of Omicron by Antibodies from the BNT162b2 Vaccination against SARS-CoV-2
por: Lanz, Tobias V., et al.
Publicado: (2022)

Antibody levels after BNT162b2 vaccine booster and SARS-CoV-2 Omicron infection
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
por: Ko, Geon Young, et al.
Publicado: (2023)

Boosting capacity of a fourth dose BNT162b2 in cancer patients
por: Debie, Yana, et al.
Publicado: (2023)

Protective antibodies and T cell responses to Omicron variant after the booster dose of BNT162b2 vaccine
por: Naaber, Paul, et al.
Publicado: (2022)

Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
por: Nemet, Ital, et al.
Publicado: (2021)

BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

The Comparability of Anti-Spike SARS-CoV-2 Antibody Tests is Time-Dependent: a Prospective Observational Study
por: Perkmann, Thomas, et al.
Publicado: (2022)

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
por: Lu, Lu, et al.
Publicado: (2022)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
por: Davidov, Yana, et al.
Publicado: (2022)

Fourth BNT162b2 vaccination neutralization of omicron infection after heart transplantation
por: Peled, Yael, et al.
Publicado: (2022)

Effectiveness and Durability of the BNT162b2 Vaccine against Omicron Sublineages in South Africa
por: Collie, Shirley, et al.
Publicado: (2022)

BNT162b2 vaccine induced variant-specific immunity, safety and risk of Omicron breakthrough infection in children aged 5 to 11 years: a cohort study
por: Yung, Chee Fu, et al.
Publicado: (2023)

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals
por: Manisty, Charlotte, et al.
Publicado: (2021)

Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance
por: Nantanee, Rapisa, et al.
Publicado: (2023)

Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron
por: Mair, Maximilian J., et al.
Publicado: (2022)

Omicron sublineage recombinant XBB evades neutralising antibodies in recipients of BNT162b2 or CoronaVac vaccines
por: Zhang, Xiaojuan, et al.
Publicado: (2023)

SARS-CoV-2 Infections in “less visible” Hospital Staff: The Roles and Safety of Environmental Services and Allied Health Professionals
por: Jensen, Sebastian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tcmgvaavri05qjhb73f3jf4jg5